SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 23, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                     Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam, RespiGam and Synagis are registered trademarks of the Company.

<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 23, 1999:

FOR IMMEDIATE RELEASE



               MEDIMMUNE COMPLETES ACQUISITION OF U.S. BIOSCIENCE

Gaithersburg,  MD, and West  Conshohocken,  PA, November 23, 1999 --- MedImmune,
Inc.  (Nasdaq:  MEDI)  and U.S.  Bioscience  (Amex:  UBS) have  completed  their
previously  announced  merger  following  today's approval of the transaction by
U.S. Bioscience  shareholders.  U.S.  Bioscience  stockholders will receive 0.15
MedImmune  shares for each U.S.  Bioscience share they own, with cash to be paid
in lieu of fractional shares.

The merger has an  approximate  equity value of $580  million,  or a transaction
value of $529 million (net of cash and investments), based on 30.5 million fully
diluted  U.S.  Bioscience  shares and  MedImmune's  last sale price as quoted on
NASDAQ on November 22, 1999 of $126.75 per share.

MedImmune,  Inc. located in Gaithersburg,  Maryland,  is a biotechnology company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.

U.S.  Bioscience,  Inc.,  based  in  West  Conshohocken,   Pennsylvania,   is  a
pharmaceutical   company   primarily   specializing   in  the   development  and
commercialization of products for patients with cancer.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number of  factors.  Risk  factors  and  uncertainties  are  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission,  including
the combined proxy statement/S-4 Registration Statement filed in connection with
the U.S. Bioscience acquisition,  and include, without limitation,  the risks to
successfully integrate the operations of the two companies.



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)



                         /s/David M. Mott
November 23, 1999        ----------------
Signed by:               David M. Mott, Vice Chairman and
                         Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE COMPLETES ACQUISITION OF U.S. BIOSCIENCE", "secsgml_size_bytes": 3832}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99763805"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 23, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                     Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

No Exhibits are being filed with this report

CytoGam, RespiGam and Synagis are registered trademarks of the Company.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 23, 1999:

FOR IMMEDIATE RELEASE

               MEDIMMUNE COMPLETES ACQUISITION OF U.S. BIOSCIENCE

Gaithersburg,  MD, and West  Conshohocken,  PA, November 23, 1999 --- MedImmune,
Inc.  (Nasdaq:  MEDI)  and U.S.  Bioscience  (Amex:  UBS) have  completed  their
previously  announced  merger  following  today's approval of the transaction by
U.S. Bioscience  shareholders.  U.S.  Bioscience  stockholders will receive 0.15
MedImmune  shares for each U.S.  Bioscience share they own, with cash to be paid
in lieu of fractional shares.

The merger has an  approximate  equity value of $580  million,  or a transaction
value of $529 million (net of cash and investments), based on 30.5 million fully
diluted  U.S.  Bioscience  shares and  MedImmune's  last sale price as quoted on
NASDAQ on November 22, 1999 of $126.75 per share.

MedImmune,  Inc. located in Gaithersburg,  Maryland,  is a biotechnology company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.

U.S.  Bioscience,  Inc.,  based  in  West  Conshohocken,   Pennsylvania,   is  a
pharmaceutical   company   primarily   specializing   in  the   development  and
commercialization of products for patients with cancer.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number of  factors.  Risk  factors  and  uncertainties  are  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission,  including
the combined proxy statement/S-4 Registration Statement filed in connection with
the U.S. Bioscience acquisition,  and include, without limitation,  the risks to
successfully integrate the operations of the two companies.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)

                         /s/David M. Mott
November 23, 1999        ----------------
Signed by:               David M. Mott, Vice Chairman and
                         Chief Financial Officer